Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2011

View Archived Issues

New carbapenem antibiotics described

Irosustat demonstrates pharmacodynamic proof of concept

New DNA vaccine is efficacious in monkey model of tuberculosis

Gantenerumab reduces amyloid levels in brain

Scientists in U.K. identify microRNA biomarker in COPD

Phase I/II data disclosed on trabedersen in melanoma, pancreatic and colorectal carcinoma

Intellikine advances first-in-human trial of INK-1117

Ironwood Pharmaceuticals prepares new GCS activators

Isis Pharmaceuticals selects second development candidate in GlaxoSmithKline collaboration

Dainippon Sumitomo Pharma discloses novel agents for sepsis

ISCO reports promising preclinical results with hpSC-derived neuronal cells

New deuterated dimethylcurcumin derivatives claimed by Concert Pharmaceuticals

Scientists at Gilead Sciences patent new SYK inhibitors

Novel histamine receptor antagonists presented by Kalypsys

Medicago completes first stage of noninfluenza VLP vaccine collaboration agreement

Michael J. Fox Foundation funds clinical study of Parkinson's disease vaccine

ISTA provides update on development of bromfenac ophthalmic solutions

Topline data reported from Pozen's phase III PA-32540 study

FDA grants pre-IND meeting to Advaxis for ADXS-HER2

DSMB recommends continuing Cyclacel's SEAMLESS trial

Micromet outlines registration strategy for blinatumomab

Kissei Pharmaceutical to pay MediciNova for further development of MN-221

Baxter International starts phase III trial of recombinant von Willebrand factor

FDA committee recommends approval of Zilver PTX paclitaxel-eluting stent

Telik commences phase IIb trial of Telintra

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...